NGM Stock Overview NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteNGM Biopharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NGM Biopharmaceuticals Historical stock prices Current Share Price US$1.54 52 Week High US$4.69 52 Week Low US$0.60 Beta 1.27 1 Month Change 1.32% 3 Month Change 14.93% 1 Year Change -59.79% 3 Year Change -93.94% 5 Year Change -90.41% Change since IPO -89.52%
Recent News & Updates NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors Jul 18
NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors Jul 17
NGM Biopharmaceuticals Files Form 15 Apr 15 The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders. Apr 06
The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million. Feb 28
NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer See more updates NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors Jul 18
NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors Jul 17
NGM Biopharmaceuticals Files Form 15 Apr 15 The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders. Apr 06
The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million. Feb 28
NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer
NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need Jan 09
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You Dec 19 NGM Biopharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Dec 05
NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting Nov 14
Consensus revenue estimates decrease by 41%, EPS upgraded Nov 09
Price target decreased by 19% to US$4.83 Nov 05
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 03
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate Oct 05
Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023 Sep 12
NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023 Aug 12
Consensus revenue estimates fall by 26% Aug 10
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates Aug 09
Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint Aug 04
Insufficient new directors Jul 01
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky Jun 27
Consensus revenue estimates decrease by 47%, EPS upgraded May 11
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 06
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't Apr 17
Consensus EPS estimates fall by 23% Mar 07
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 01
Founder exercised options and sold US$316k worth of stock Jan 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully Dec 20
NGM Biopharmaceuticals, Inc. Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting Dec 09
Price target increased to US$6.20 Nov 16
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting Nov 08
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 04
Ngm Biopharmaceuticals, Inc. Announces Presentation of Post-Hoc Analyses from Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration At the Retina Society Annual Scientific Meeting Nov 04
Lead Independent Director recently bought US$462k worth of stock Oct 21
Ngm Biopharmaceuticals, Inc. (Ngm Bio) Announces Topline Efficacy and Safety Results from Its Randomized, Double-Masked, Sham-Controlled Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration Oct 18
Price target decreased to US$28.75 Oct 18
NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails Oct 17
Consensus revenue estimates fall by 11% Aug 13
Consensus revenue estimates fall by 22% Aug 11
Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.48 loss in 2Q 2021) Aug 05
Price target decreased to US$32.50 Jul 20
NGM Biopharmaceuticals, Inc. Announces Executive Changes Jul 01
NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President Jun 30
NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022 Jun 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth Jun 15
NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/1B Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors May 13
Consensus forecasts updated May 12
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week May 09
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat May 06
NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad Apr 26
NGM Biopharmaceuticals, Inc. to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio Apr 09
NGM Biopharmaceuticals, Inc., Annual General Meeting, May 18, 2022 Apr 07
NGM Biopharmaceuticals, Inc. Announces It Has Dosed the First Patient in A Phase 1/1B Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors Apr 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 04
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth Feb 21
CEO & Director exercised options to buy US$313k worth of stock. Jan 01
Founder notifies of intention to sell stock Dec 10
Founder notifies of intention to sell stock Nov 19
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely Nov 08
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.43 loss in 3Q 2020) Nov 06
High number of new directors Oct 31
Founder notifies of intention to sell stock Oct 15
Founder notifies of intention to sell stock Sep 17
Price target increased to US$31.50 Sep 12
NGM Biopharmaceuticals, Inc. Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research Aug 25
Chief Medical Officer & Senior VP recently sold US$52k worth of stock Aug 17
Founder notifies of intention to sell stock Aug 13
Second quarter 2021 earnings released: US$0.48 loss per share (vs US$0.38 loss in 2Q 2020) Aug 08
Consensus EPS estimates fall to -US$1.70 Aug 07
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth Jul 09
Independent Director McHenry Tichenor has left the company Jun 11
Independent Director David Schnell has left the company Jun 11
Founder exercised options to buy US$1.2m worth of stock. Jun 10
NGM Biopharmaceuticals, Inc. Reports Topline Results from 24-Week Phase 2B Alpine 2/3 Study of Aldafermin in NASH May 25
Price target decreased to US$26.50 May 25
Consensus forecasts updated May 25
Founder notifies of intention to sell stock May 08
First quarter 2021 earnings released: US$0.36 loss per share (vs US$0.28 loss in 1Q 2020) May 08
Founder notifies of intention to sell stock Apr 16
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year Mar 06 Shareholder Returns NGM US Pharmaceuticals US Market 7D -3.1% -0.3% -2.7% 1Y -59.8% 7.9% 23.4%
See full shareholder returns
Return vs Market: NGM underperformed the US Market which returned 24.7% over the past year.
Price Volatility Is NGM's price volatile compared to industry and market? NGM volatility NGM Average Weekly Movement 10.3% Pharmaceuticals Industry Average Movement 10.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: NGM's share price has been volatile over the past 3 months.
Volatility Over Time: NGM's weekly volatility (10%) has been stable over the past year.
About the Company NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy.
Show more NGM Biopharmaceuticals, Inc. Fundamentals Summary How do NGM Biopharmaceuticals's earnings and revenue compare to its market cap? NGM fundamental statistics Market cap US$128.53m Earnings (TTM ) -US$142.37m Revenue (TTM ) US$4.42m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NGM income statement (TTM ) Revenue US$4.42m Cost of Revenue US$114.23m Gross Profit -US$109.81m Other Expenses US$32.56m Earnings -US$142.37m
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -1.71 Gross Margin -2,486.12% Net Profit Margin -3,223.34% Debt/Equity Ratio 0%
How did NGM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/04/05 02:23 End of Day Share Price 2024/04/05 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NGM Biopharmaceuticals, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Luchini BMO Capital Markets Equity Research Mayank Mamtani B. Riley Securities, Inc. Paul Choi Goldman Sachs
Show 5 more analysts